Overview

This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.

Eligibility

Inclusion Criteria:

• Histologically-proven metastatic prostate cancer
• Presence of low-volume or high-volume metastases (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.)
• Planned to or receiving systemic treatment ADT +/- ARAT as per physician discretion (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.)
• Planned for EBRT
• ECOG 0 or 1
• Age 18 years or older

Exclusion Criteria:

• Prior radiotherapy to pelvis
• Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
• Any condition where radiotherapy is contraindicated